Taylor Taylor
Family · Normal, ILNPI 1427538198
Payments from drug & device makers
Across 144 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$505
- Sumitomo Pharma America, Inc.$465
- Biogen$249
- Pfizer$222
- Scynexis, Inc.$205
- Exeltis, USA Inc.$179
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,07697%
- Education$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 21 | $505 |
| Sumitomo Pharma America, Inc. | 22 | $465 |
| Biogen | 13 | $249 |
| Pfizer | 12 | $222 |
| Scynexis, Inc. | 3 | $205 |
| Exeltis, USA Inc. | 12 | $179 |
| Novo Nordisk | 3 | $148 |
| Bayer | 8 | $134 |
| Johnson & Johnson | 1 | $124 |
| Organon | 6 | $110 |
| Daiichi Sankyo Inc. | 5 | $96 |
| Axsome Therapeutics, Inc. | 4 | $79 |
| Avion Pharmaceuticals | 5 | $78 |
| Urovant Sciences Inc | 4 | $72 |
| AbbVie | 4 | $72 |
| Hologic Sales And Service, LLC | 3 | $55 |
| Lilly USA, LLC | 2 | $55 |
| Mayne Pharma Commercial LLC | 2 | $44 |
| Exact Sciences | 2 | $43 |
| Coopersurgical, Inc. | 1 | $42 |
| Myovant Sciences Inc. | 2 | $38 |
| Heron Therapeutics, Inc. | 1 | $24 |
| Vertex | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Conmed Corporation | 1 | $19 |
| Evofem Biosciences, Inc. | 1 | $17 |
| Davol Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Olympus America Inc. | 1 | $14 |
| Convatec Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,171 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 13 | $7,997 |
| MyrbetriqMirabegron | 13 | $6,013 |
| ValacyclovirValacyclovir Hcl | 33 | $2,148 |
| Estradiol | 59 | $1,940 |
| Estradiol (Twice Weekly)Estradiol | 12 | $1,423 |
| Clobetasol Propionate | 12 | $321 |
| Fluconazole | 16 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $222 | $7,99713 claims |
| Astellas Pharma US IncMyrbetriq | $505 | $6,01313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.
Other family in Normal
- Kathleen LallyNormal$14K
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.